Topical Brimonidine Tartrate 0.33% Gel on Postlaser Erythema: Our Experience and Review of the Literature

摘要

Gerber1 has recently reported good control of daylight-activated photodynamic therapy (DL-PDT) erythema with topical brimonidine tartrate (BT) 0.33% gel. Lasers and intense pulsed light (LPL) produce varying degrees of post-treatment erythema, which is comparable with that of DL-PDT. We herein occur. Therefore, we recommend caution in applying BT as well as other alpha-agonists immediately after lasers and IPL. We also strongly discourage its use following ablative procedures, which substantially increase BT absorption and the risk of systemic toxicity.